Associations between 25-Hydroxyvitamin D and Immunologic, Metabolic, Inflammatory Markers in Treatment-Naive HIV-Infected Persons: The ANRS CO9 «COPANA» Cohort Study

Camille Legeai1,10, Corinne Vigouroux2,3,4, Jean-Claude Souberbielle5, Olivier Bouchaud6,7, Faroudy Boufassa1, Jean-Philippe Bastard2,3, Robert Carlier8, Jacqueline Capeau2,3,4, Cécile Goujard1,9,10, Laurence Meyers1,10,11, Jean-Paul Viard12,13,*, the ANRS-COPANA Cohort Study Group

1 Institut National de la Santé et de la Recherche Médicale (INSERM), unité mixte de recherche et de service (UMRS) 1018, équipe « Épidémiologie du VIH et des infections sexuellement transmissibles », centre de recherche en épidémiologie et santé des populations (CESP)-INSERM U1018, Le Kremlin-Bicêtre, France, 2 Assistance Publique-Hôpitaux de Paris, service de radiologie et imagerie médicale, hôpital Raymond-Poincaré, Garches, France, 3 Assistance Publique-Hôpitaux de Paris, service des maladies infectieuses, hôpital Avicenne, Bobigny, France, 4 Université Pierre et Marie Curie-Paris 06, institute of cardiometabolism and nutrition (ICANI), Paris, France, 5 Assistance Publique-Hôpitaux de Paris, service d'explorations fonctionnelles, hôpital Necker, Paris, France, 6 Assistance Publique-Hôpitaux de Paris, service des maladies infectieuses, hôpital Avicenne, Bobigny, France, 7 Université Paris-Nord, Bobigny, France, 8 Assistance Publique-Hôpitaux de Paris, service de radiologie et imagerie médicale, hôpital Raymond-Poincaré, Garches, France, 9 Assistance Publique-Hôpitaux de Paris, service de médecine interne, hôpital Bicêtre, Le Kremlin-Bicêtre, France, 10 Université Paris-Sud, Le Kremlin-Bicêtre, France, 11 Assistance Publique-Hôpitaux de Paris, service d'épidémiologie et de santé publique, hôpital Bicêtre, Le Kremlin-Bicêtre, France, 12 Assistance Publique-Hôpitaux de Paris, centre de diagnostic et de thérapeutique, Hôpital Hôtel-Dieu, Paris, France, 13 Équipe d’accueil 3620, Université Paris Descartes, Paris, France

Abstract

Objectives: Low 25(OH)D has been associated with dyslipidemia, insulin resistance and inflammation in both general and HIV-infected (mostly treated) populations. We investigated these associations in antiretroviral-naïve HIV-infected persons.

Design: We measured plasma 25(OH)D, metabolic, immunologic and inflammatory markers in 355 persons (204 Whites, 151 Blacks) at enrollment in the ANRS COPANA cohort.

Methods: 25(OH)D levels were categorized <10 ng/mL (severe deficiency) and <20 ng/mL (deficiency). Statistical analyses were adjusted for sampling season, ethnicity and the interaction between season and ethnicity.

Results: 25(OH)D insufficiency (<30 ng/mL), deficiency (<20 ng/mL) and severe deficiency (<10 ng/mL) were highly prevalent (93%, 67% and 24% of patients, respectively). Blacks had significantly lower 25(OH)D than Whites (median: 13 vs. 17 ng/mL, P<0.001), with markedly less pronounced seasonal variation. Smoking and drinking alcohol were associated with having a 25 OHD level<10 ng/mL. In patients with 25(OH)D<10 ng/mL, the proportion of persons with a CD4 count<100/ mm³ was higher than in patients with 25(OH)D≥10 ng/mL (18.8% vs. 10.7%, P=0.04). Persons with 25 OHD<10 ng/mL had higher levels of hsCRP (1.60 mg/L [IQR: 0.59–5.76] vs. 1.27 mg/L [0.58–3.39], P=0.03) and resistin (16.81 ng/L [IQR: 13.82–25.74] vs. 11.56 ng/L [IQR: 8.87–20.46], P=0.02), and, among Blacks only, sTNFR2 (2.92 ng/mL [2.31–4.13] vs. 2.67 ng/mL, [1.90–3.23], P=0.04). The strength and significance of the association between CD4<100/mm³ and 25 OHD<10 ng/mL were reduced after adjustment on sTNFR1, sTNFR2, and hsCRP levels. In multivariate analysis, a CD4 count <100/mm³, resistin concentration and smoking were independently associated with 25(OH)D<10 ng/mL.

Conclusions: Severe vitamin D deficiency was associated with low CD4 counts and increased markers of inflammation in ARV-naive HIV-infected persons.
**Introduction**

In the general population, vitamin D deficiency, assessed by low levels of 25-hydroxy vitamin D (25(OH)D), has been associated with diverse conditions, of which many have become of concern in the HIV-infected population, such as infections, cardiovascular disease, insulin resistance and diabetes, dyslipidemia, cancer, neurocognitive impairment, frailty, renal function alteration, osteopenia/osteoporosis, and autoimmune diseases [1–4]. It has also been associated with all-cause and cardiovascular mortality in persons weakened by age [5] or chronic conditions such as high cardiovascular risk [6], diabetes [7], cancer [8], heart transplant- tion [9] and renal failure [10].

Studies in HIV-infected persons, mostly antiretroviral-treated, showed that vitamin D deficiency is not more prevalent than in the general population [11,12]. However, besides factors usually associated with vitamin D deficiency (e.g. phenotype, season, region), HIV disease parameters such as a low CD4 count and exposure to antiretrovirals have been associated with low 25(OH)D levels [11]. Whatever the causes of lowered 25(OH)D in HIV-infected persons, the known associations of vitamin D deficiency with inflammation [13,14], activation of coagulation [15], and impaired T-cell function [16] makes it a plausible cofactor in the pathogenesis of clinical complications and comorbidities of HIV infection. Indeed, vitamin D deficiency has been associated with clinical and pre-clinical endpoints in HIV-infected persons: all-cause mortality during untreated [17] and treated [18,19] HIV infection, lesser CD4 cell gain on antiretroviral therapy [20,21], AIDS and non-AIDS-defining events [18,22,23], insulin resistance [24], type 2 diabetes [25], and atherosclerosis [26–28]. Altogether, these data suggest that treated and untreated HIV-infected persons might be particularly susceptible to the deleterious effects of vitamin D deficiency.

The interpretation of studies in treated patients is hampered by the effects of antiretroviral drugs, their metabolic adverse events, and their possible impact on vitamin D metabolism [11]. The present study investigated for the first time the associations between 25(OH)D levels and body composition, metabolic, immunologic and inflammatory markers in a large group of White and Black antiretroviral-naïve HIV-1-infected persons enrolled soon after HIV diagnosis.

**Methods**

**Study Design**

The ANRS-C09-COPANA cohort is an ongoing prospective study conducted in 37 hospitals in France. Between 2004 and 2008, it enrolled 800 recently diagnosed (<1 year) HIV-1-infected adults, antiretroviral naive at baseline, with standard procedures. The Paris-Cochin Ethics Committee approved the study protocol and all participants gave written informed consent. At enrollment and each scheduled visit, detailed sociodemographic, clinical and biological data were collected. Patients who accepted to participate entered a metabolic substudy comprising an oral glucose tolerance test (OGTT), measurements of inflammatory markers, insulin and adipokines, computed tomography (CT) at the level of the L4 vertebra and dual-energy X-ray absorptiometry (DEXA) [29]. 25(OH)D was measured in plasma samples taken at enrollment from 355 patients of Black or White ethnicity (patients in the metabolic study and patients selected for a longitudinal study on the basis of remaining treatment-naïve at 1 year of follow-up).

**Measurements**

Age, gender, ethnicity, smoking, alcohol consumption, HIV transmission category, blood pressure, height, weight, body mass index (BMI) and waist circumference were documented at enrollment. CD4 cell count, HIV RNA viral load, blood levels of fasting lipids, glucose and creatinine, were measured at each center with standard procedures. The MDRD equation was used for calculation of the estimated glomerular filtration rate (eGFR). 25(OH)D was measured on cryopreserved plasma samples at Necker Hospital, Paris, using the DiaSorin® radioimmunassay. Sampling season was defined as summer/autumn for patients sampled in June – November, and as winter/spring for those sampled in December – May. In patients enrolled in the metabolic substudy, glycaemia and insulinaemia were measured at T0 and T120 minutes of an OGGT (75 g of glucose) performed after at least 8-hour fast. Inflammatory markers, insulin and adipokines levels were measured on cryopreserved serum samples at Tenon Hospital, Paris. Insulin was measured with a method avoiding cross-reactivity with pro-insulin (ARCHITECT system; Abbott, North Chicago, IL, USA). Homeostasis model assessment of insulin resistance (HOMA-IR) values was calculated as [T0 insulin (mU/L) × T0 glucose (mmol/L)/22.5]. High sensitivity C-reactive protein (hsCRP) was determined by nephelometry on an IMMAGE analyser (Beckman-Coulter, Villepinte, France). Serum total adiponectin, resistin, leptin, interleukin (IL)-6, monococyte chemoattractant protein-1 (MCP-1), tumor necrosis factor (TNF)-α and its soluble receptors sTNFR 1 and 2 were measured with multiplexed bead-based immunoassays (Linco Research Inc., St. Charles, MO, USA and Biosource International Inc.; Camarillo, CA, USA), with respective detection limits of 145.6, 6.7, 85.4, 1.6, 0.14, 0.14, 15 and 15 pg/mL, on a Bio-Plex 200 system (Bio-Rad laboratories Inc., Hercules, CA, USA) using BioPlex Manager TM 3.0 software.

Subcutaneous and visceral adipose tissue areas (SAT and VAT) were calculated in the same radiological center, from 1-cm reconstructed slices of abdominal L4 CT scans, using an Extended Brilliance workstation and QCTA software (EBW, QCTA, Philips Medical Systems, Eindhoven, the Netherlands). DEXA was performed using Lunar Prodigy (GE Medical Systems, Madison, WI, USA) or Hologic (Hologic, Inc., Bedford, MA, USA) densitometers and percentages of total, trunk and limb fat were recorded.

**Statistical Analysis**

Continuous variables were reported as medians and 25th to 75th percentiles (IQR), and compared according to baseline characteristics by using non-parametric Wilcoxon tests. Categorical variables were reported as percentages and compared by using χ² or Fisher’s tests. The LOESS method was used to plot a smooth curve showing 25(OH)D level variations according to sampling season in White and Black patients. Multiple linear regression models were used to explore association between 25(OH)D levels and ethnicity and sampling season (P-values were estimated by the Wald tests).

The analysis performed within the EuroSIDA study showed that increased risks of AIDS-defining events and all-cause death were associated with very low 25(OH)D levels, <12 ng/mL, which is very close to the commonly accepted definition of severe deficiency (<10 ng/mL) [18]. We therefore decided to classify patients into 2 categories according to severely deficient status (25(OH)D<10 ng/mL and ≥10 ng/mL). We also classified patients according to deficient status (25(OH)D<20 ng/mL and ≥20 ng/mL).
Associations between 25(OH)D severely deficient or deficient status and socio-demographic characteristics, immuno-virologic, inflammatory and metabolic markers were explored using logistic regression models; P-values were estimated by the Wald tests, and analyses were systematically adjusted for season, ethnicity and season-ethnicity interaction. Multivariate analysis was performed by logistic regression. All variables associated with severe vitamin D deficiency with a $P \leq 0.10$ after adjustment for season, ethnicity and season-ethnicity interaction were included in the initial model, except visceral adipose tissue measurement due to the statistical power issue. Backward stepwise selection process of variables with $P < 0.10$ was used to determine the final multivariate logistic model; season, ethnicity and season-ethnicity interaction were forced into the model.

We further explored whether the association between severe immunodeficiency and low levels of 25(OH)D could be explained by increased levels of inflammatory markers. To do so, we used a multivariate logistic model assessing the association between severe immune deficiency (as the dependent variable) with severe vitamin D deficiency and inflammatory markers. Several models were built, one per inflammatory marker.

Statistical analyses were performed using SAS software version 9.2 (SAS Institute, Cary, NC, USA).

**Results**

**Baseline Characteristics**
Among the 355 patients, 108 (30%) were women and 150 (42%) were men having sex with men (MSM), 97% of patients having been infected by the sexual route. At enrollment, median age was 36 years (IQR: 30–44) and median BMI was 23.0 kg/m² (IQR: 20.8–25.7). Median duration since HIV diagnosis was 3.8 months (IQR: 1.5–7.1), median HIV-1 RNA level was $4.6 \log_{10}$ copies/mL (IQR: 4.1–5.2), median CD4+ T-cell count was 300/mm³ (IQR: 173–463) and 34 patients (9.6%) were at CDC stage C of infection, 151 (43%) patients were Black (134 of African and 17 of Afro-Caribbean origin). Compared to Whites, Black patients were younger (median age: 34 vs. 37 years, $P = 0.03$), more often female (55% vs. 12%, $P < 0.001$) or heterosexual men (70% vs. 24% of the men, $P < 0.001$), they had a higher BMI (median: 23.9 vs. 22.5, $P < 0.001$) and their median CD4+ T-cell count was lower (245 vs. 344/mm³, $P < 0.001$).

**Low 25(OH)D Concentrations in Antiretroviral-naïve, Recently Diagnosed HIV-infected Patients**
A vast majority of the patients (93%) had vitamin D insufficiency, i.e. 25(OH)D $<30$ ng/mL. Criteria for vitamin D deficiency ($<20$ ng/mL) or severe deficiency ($<10$ ng/mL) were met by 67 and 24% of the patients, respectively.

Patients sampled in winter/spring had a much lower 25(OH)D level than those sampled in summer/autumn: median of 13 ng/mL (IQR: 9–19.5) vs. 18 ng/mL (IQR: 12–24) ($P < 0.001$). Median 25(OH)D was significantly lower in Black than in White patients, even after adjustment for age, sex, sampling season and BMI: adjusted mean 13.9 ng/mL (95%CI: 12.5–15.3) in Blacks vs. 18.7 ng/mL (95%CI: 17.3–20.1) in Whites, ($P < 0.001$).

As illustrated by figure 1, season’s impact on 25(OH)D plasma concentrations was markedly less pronounced in Black than in White patients. In a linear regression model, season ($P < 0.001$),...
Association between Severe Vitamin D Deficiency, Clinical Characteristics and Biomarkers (Table 1)

Tobacco smokers and persons drinking more than 20 g of alcohol a day were significantly overrepresented among patients with severe vitamin D deficiency. The same trend, not reaching statistical significance ($P=0.08$), was noted for non-MSM, compared with MSM.

Patients with 25(OH)D concentrations below 10 ng/mL had a more severe immune deficiency than patients with 25(OH)D $\geq$ 10 ng/mL, since 18.8% vs. 10.7% had a CD4 count $<$ 100/mm$^3$ ($P=0.04$). They also had higher levels of the inflammatory markers hsCRP (1.60 mg/L [IQR: 0.95–6.57] vs. 1.27 mg/L [0.83–3.39], $P=0.03$), and resistin (16.81 ng/L [13.82–25.74] vs. 11.56 ng/L [8.37–20.46], $P=0.02$), and they tended to have lower TNF-$\alpha$ levels, but this did not reach significance ($P=0.07$).

Patients with 25(OH)D $<$ 10 ng/mL also had a lower amount of VAT: 66.8 cm$^2$ [43.3–75.9] vs. 71.3 cm$^2$ [44.0–112.9] ($P=0.02$), although BMI, total body fat, serum leptin and adiponectin were not significantly different as compared to the other patients.

Persons with plasma 25(OH)D $\geq$ 20 ng/mL had a lower estimated glomerular filtration rate (eGFR) (95.7 mL/min/1.73 m$^2$ [84.3–110.7] vs. 102.9 mL/min/1.73 m$^2$ [87.5–120.2], unadjusted $P=0.02$, Wilcoxon’s rank test). However, we did not find a dose-effect curve for this marker. Indeed, persons with plasma 25(OH)D $\geq$ 20 ng/mL were those who more often had an eGFR lower than 90 mL/min/1.73 m$^2$ (OR [95%CI]: 1.70 [1.03–2.80], $P=0.04$, adjusted for season and ethnicity).

In multivariate analysis, a CD4 count below 100/mm$^3$, resistin concentration and being a smoker remained independently associated with severe vitamin D deficiency.

There was no significant association between 25(OH)D severe deficiency and other markers, including glycermia, insulinemia, triglycerides, and total, HDL or LDL cholesterol.

Since 25(OH)D concentrations were significantly lower, with much less seasonal variations, in Black persons, we examined whether ethnicity modified the relations between 25(OH)D and the variables we examined. There was a significant interaction ($P=0.04$) between ethnicity and sTNFR2 concentration, which was in Black patients only, significantly higher in the severely vitamin D deficient group compared to patients with 25(OH)D $\geq$ 10 ng/mL (in Blacks: 2.92 ng/mL [2.31–4.13] vs. 2.67 ng/mL [1.90–3.23], $P=0.04$; in Whites: 2.29 ng/mL [1.53–2.71] vs. 2.49 ng/mL [2.02–3.10], $P=0.30$).

Low CD4 Counts, Severe Vitamin D Deficiency, and Inflammatory Markers

We further investigated the relationship between severe immune deficiency (CD4 $<$ 100/mm$^3$) and severe vitamin D deficiency by testing different models comprising vitamin D ($<$ 10 ng/mL vs. $\geq$ 10 ng/mL) and several inflammatory markers. After adjustment for either hsCRP, sTNFR1 or sTNFR2, the significance and magnitude of the association between severe vitamin D deficiency and having a CD4 count $<$ 100/mm$^3$ were reduced (Table 2), suggesting that these markers could in part explain this association. On the other hand, adjustment for resistin, IL-6, MCP-1 and TNF-$\alpha$ did not weaken the relationship between vitamin D deficiency and low CD4 counts.

Analysis of patients with vitamin D deficiency (25(OH)D $<$ 20 ng/mL). When classifying patients as vitamin D-deficient (25(OH)D $<$ 20 ng/mL) vs. non-deficient (25(OH)D $\geq$ 20 ng/mL), the analysis confirmed that higher 25(OH) levels were associated with lower eGFR (cf. supra). Although showing the same trends, none of the other relationships described above remained statistically significant (data not shown). On the other hand, leptin concentration was significantly higher in vitamin-D deficient patients (3.63 mg/L [1.20–9.50] vs. 3.39 mg/L [1.65–10.55], $P=0.03$), which was not observed when using a 25(OH)D cut-off of 10 ng/mL.

Discussion

We show herein that severe vitamin D deficiency is associated with very low CD4 counts (< 100/mm$^3$) and inflammation in untreated HIV infection. HIV infection is a risk factor for metabolic abnormalities and cardiovascular disease [30]. Antiretroviral drugs may play an additional role in the occurrence of these conditions, as shown by the risk for myocardial infarction conveyed by the exposure to protease inhibitors [31]. Research has recently focused on the role of HIV infection itself, treated or not, since inflammation and T-cell/monocyte activation have been associated with pre-clinical and clinical cardiovascular endpoints [30,32]. Untreated HIV infection leads to an unfavorable lipid profile [33] and we have shown that immune deficiency in treatment-naive patients is associated with insulin resistance [29]. Since vitamin D insufficiency has been associated with metabolic abnormalities, inflammation, and pre-clinical markers of atherosclerosis in both the general and HIV-infected populations, we explored the relations between 25(OH)D levels and body composition, metabolic, immunologic, and inflammatory markers in recently diagnosed antiretroviral-naive HIV-infected patients.

25(OH)D Low Levels in Black and White Patients

Vitamin D insufficiency, deficiency, and severe deficiency were frequent in this population of antiretroviral-naive patients (found in 93%, 67% and 24% of cases, respectively). Low 25(OH) levels were associated with smoking in the multivariate analysis, as previously reported [34]. The 25(OH)D concentration was much lower in Black than in White persons. Interestingly, while the expected association between the level of 25(OH)D and the season of sampling was confirmed in Black as well as White patients, seasonal variation was much less pronounced in Black persons. Since it is not known whether the influence of a low 25(OH)D level on cell functions and blood markers is short- or mid/long-term, this could put Black persons at a higher risk of deleterious consequences of vitamin D deficiency, because smaller variations around the year reduce the probability of reaching desirable 25(OH)D levels.
### Table 1. Characteristics of patients according to severe vitamin D deficiency.

| Variables expressed as median [IQR] or N (%) | N       | 25-hydroxyvitamin D categories | P value * |
|--------------------------------------------|---------|-------------------------------|----------|
|                                            |         | <10 ng/mL                     | ≥10 ng/mL|
| Sampling during Winter/Spring              | 200     | 60 (70.6)                     | 140 (51.9)|
| Sampling during Summer/Autumn              | 155     | 25 (29.4)                     | 130 (48.1)| <0.01 |
| Age (years)                                | 355     | 35 [30–44]                    | 36 [30–43] | 0.92 |
| Male                                       | 247     | 59 (69.4)                     | 188 (69.6)| 0.76 |
| Female                                     | 108     | 26 (30.6)                     | 82 (30.4)| 0.76 |
| Non MSM                                    | 210     | 58 (68.2)                     | 152 (56.3)| 0.08 |
| MSM                                        | 145     | 27 (31.8)                     | 118 (43.7)| 0.08 |
| Non smokers                                | 236     | 50 (58.8)                     | 186 (69.1)| 0.02 |
| Smokers                                    | 118     | 35 (41.2)                     | 83 (30.9)| 0.02 |
| Alcohol intake <20 g/day                   | 293     | 68 (85.0)                     | 225 (90.4)| 0.05 |
| Waist circumference (cm)                   | 325     | 82 [75.5–87.5]                | 83 [77.0–90.0] | 0.40 |
| Body mass index (BMI)                      | 347     | 22.1 [20.3–24.7]              | 23.1 [21.1–25.9] | 0.11 |
| BMI ≥30                                    | 325     | 79 (96.3)                     | 246 (92.8)| 0.02 |
| Total body fat assessed by DEXA (%)        | 106     | 19.58 [11.9–30.0]             | 20.8 [14.0–28.9] | 0.36 |
| SAT assessed by CT scan (cm²)              | 147     | 126.1 [73.8–192.8]            | 140.4 [82.5–196.5] | 0.36 |
| VAT assessed by CT scan (cm²)              | 147     | 66.8 [43.3–75.9]              | 71.3 [44.0–112.9] | 0.02 |
| eGFR, MDRD formula (mL/min/1.73 m²)        | 343     | 102.9 [87.5–120.2]            | 95.7 [84.3–110.7] | 0.26 |
| Plasma HIV RNA (log10 copies/mL)           | 349     | 4.7 [4.0–5.21]                | 4.6 [4.0–5.1] | 0.87 |
| Baseline CD4 count (cells/mm³)             | 355     | 288 [162–488]                 | 300 [179–437] | 0.72 |
| Patients with CD4 count <100/mm³           | 45      | 16 (18.8)                     | 29 (10.7) | 0.04 |
| Patients with CD4 count ≥100/mm³           | 310     | 69 (81.2)                     | 241 (89.3) | 0.04 |
| Patients with CD4 count <200/mm³           | 101     | 29 (34.1)                     | 72 (26.7) | 0.03 |
| Patients with CD4 count ≥200/mm³           | 254     | 56 (85.9)                     | 198 (73.3) | 0.13 |
| IL-6 (pg/mL)                               | 196     | 2.87 [0.92–7.15]              | 2.74 [1.04–5.06] | 0.80 |
| hsCRP (mg/L)                               | 201     | 1.60 [0.59–5.76]              | 1.27 [0.58–3.39] | 0.03 |
| TNF-α (pg/mL)                              | 198     | 5.63 [3.72–7.89]              | 6.78 [4.30–9.41] | 0.07 |
| sTNFR1 (ng/mL)                             | 196     | 1.84 [1.50–2.27]              | 1.72 [1.28–2.16] | 0.10 |
| sTNFR2 (ng/mL)                             | 196     | 2.59 [1.96–3.21]              | 2.56 [1.98–3.23] | 0.47 |
| MCP-1 (pg/mL)                              | 200     | 206.7 [143.5–317.7]           | 218.3 [153.9–334.8] | 0.78 |
| Resistin (ng/L)                            | 125     | 16.81 [13.82–25.74]           | 11.56 [8.87–20.46] | 0.02 |
| Leptin (µg/L)                              | 198     | 3.52 [0.77–6.84]              | 3.96 [1.48–10.87] | 0.10 |
| Adiponectin (µg/L)                         | 171     | 14.56 [10.54–18.56]           | 14.71 [9.07–18.25] | 0.17 |
| Triglycerides (mmol/L)                     | 327     | 0.96 [0.63–1.65]              | 0.97 [0.67–1.40] | 0.30 |
| Total cholesterol (mmol/L)                 | 330     | 4.30 [3.74–4.78]              | 4.27 [3.64–4.90] | 0.81 |
| HDL cholesterol (mmol/L)                   | 321     | 1.11 [0.92–1.31]              | 1.11 [0.87–1.37] | 0.79 |
| LDL cholesterol (mmol/L)                   | 320     | 2.61 [2.10–2.98]              | 2.60 [2.09–3.21] | 0.50 |
| Glycemia (mmol/L, fasting)                 | 324     | 4.6 [4.3–5.0]                 | 4.8 [4.4–5.2] | 0.15 |
| Glycemia (mmol/L, OGTT t120)               | 179     | 5.2 [4.6–5.7]                 | 5.0 [4.2–5.8] | 0.93 |
| Insulinemia (mU/L, fasting)                | 202     | 5.6 [3.2–8.6]                 | 5.3 [3.8–8.2] | 0.96 |
| Insulinemia (mU/L, OGTT t120)              | 166     | 19.5 [8.4–32.3]               | 17.85 [9.3–31.3] | 0.84 |
| HOMA-IR index                              | 190     | 1.19 [0.70–1.98]              | 1.09 [0.80–1.72] | 0.75 |

*except for the season variable, P values obtained from models including season, ethnicity, season-ethnicity interaction, and the considered variable.

IQR: interquartile range, NA: not applicable, DEXA: dual energy X-ray absorptiometry, SAT: subcutaneous adipose tissue, VAT: visceral adipose tissue, CT: computed tomography, eGFR: estimated glomerular filtration rate, IL-6: interleukin 6, hsCRP: high sensitivity C-reactive protein, TNF: tumor necrosis factor, sTNFR: soluble TNF receptor, OGTT t120: oral glucose tolerance test (sample taken 120 minutes after glucose administration), HOMA-IR: homeostatic model assessment of insulin resistance. doi:10.1371/journal.pone.0074868.t001
Association of Severe Vitamin D Deficiency Levels with Low CD4 Counts and Inflammation

We confirm an inverse relation between 25(OH)D levels and immunodeficiency [12], with the proportion of persons with a CD4 count below 100/mm³ being higher in persons with 25(OH)D<10 ng/mL. This finding, in a population where there is no influence of antiretrovirals on the CD4 level, could be explained by the role played by the vitamin D/vitamin D receptor system in activation and TCR signaling in naïve T cells [16], and fits well with data showing that vitamin D deficiency is associated with clinical progression of untreated [17] or treated [18,19] HIV disease, including AIDS-defining events [18], and with a poorer CD4 restoration on treatment [20,21].

The strength and significance of the association between CD4<100/mm³ and 25 OHD<10 ng/mL were reduced after adjustment on sTNFR or hsCRP level. It is therefore possible to hypothesize that the association between severe vitamin D deficiency and immune deficiency may be mediated by uncontrolled inflammation, which should be tested in intervention trials.

Indeed, in patients with very low 25(OH)D levels, we found higher levels of the inflammatory marker hsCRP, and of resistin, which is also considered as an inflammatory marker in human, in addition to its promoting role on insulin resistance and cardiovascular diseases [33]. Very low 25 OHD at inclusion in the cohort were also associated with higher levels of hsCRP and sTNFR1 after one year of follow-up without treatment. Interestingly these associations were not found in patients with vitamin D deficiency (25(OH)D<20 ng/mL), which suggests a threshold effect rather than a dose-response curve.

Vitamin D deficiency has already been associated with higher levels of inflammatory markers in different conditions [patients at a high cardiovascular risk or with arthritis, older persons] [6,13]. In placebo-controlled studies, vitamin D supplementation has been shown to lower the level of the inflammatory cytokine TNF-α and to increase the level of the anti-inflammatory cytokine IL-10, in patients with heart insufficiency [14], and to lower markers of inflammation and immune cell activation in tuberculosis [36]. Since cross-sectional studies such as the one presented here do not allow any conclusion on the temporality or causality of the relationships, the impact of vitamin D status on pro-inflammatory markers in HIV infection should be further studied, in intervention trials.

25(OH)D, Lipids and Insulin Resistance

We found no association between triglyceride levels, cholesterol or its fractions, glycemia, insulinemia, and severe vitamin D deficiency (<10 ng/mL) or deficiency (<20 ng/mL). Previous cross-sectional studies showed an inverse relation between vitamin D levels and lipids, but intervention studies have given divergent results regarding the effect of vitamin D supplementation on serum lipids [37].

A previously published study, involving mainly Caucasian patients treated with antiretrovirals, found a correlation between low 25(OH)D and high insulin levels, but not lipatrophy or hypoalphadiponectinemia [24]. In contrast, in this antiretroviral-naive study population, we found no significant relation between 25(OH)D and fasting insulinemia. Antiretroviral drugs and their metabolic side effects could explain this discrepancy.

25(OH)D, Body Composition and Adipokines

In patients with 25(OH)D<10 ng/mL, we observed lower values of VAT, while there was no association with BMI, leptin or adiponectin. On the other hand, patients with 25(OH)D levels in the deficient range (<20 ng/mL) had significantly higher blood leptin.

Vitamin D, being liposoluble, can be trapped in adipose tissue, explaining why obesity is associated with low 25(OH)D levels, which transiently increase after bariatric surgery, probably reflecting 25(OH)D release during weight loss [38]. On the other hand, severe malnutrition can be associated with low 25(OH)D. In the setting of HIV infection, a study, in mostly treated patients, showed a trend towards lower 25(OH)D levels in persons both in the lower and higher BMI tertiles [18]. Thus, the relationships between vitamin D levels, fat mass and adipokine production are probably complex and dynamic: 1–25(OH)2D has been shown to attenuate adiponectin production [39], and to suppress leptin secretion [40] in cultured human adipocytes, while leptin has been shown to stimulate fibroblast growth factor 23 expression and to suppress 1α-hydroxylation of vitamin D in a murine model [41]. This network of interactions may explain why no straightforward relationship was observed between 25(OH)D and adiposity or adipokine levels in this cross-sectional of HIV-infected persons, in whom ongoing inflammation also probably interferes with adipocyte functions.

25(OH)D and Renal Function

We found a trend towards an inverse association between 25(OH)D levels and MDRD-estimated GFR in treatment-naïve patients. This finding has been previously reported in HIV-infected patients, but a large majority was treated with antiretrovirals [11,34]. In a setting where there is no influence of antiretrovirals on kidney function, this intriguing finding could be related to a recently described effect of vitamin D receptor
activation, which was shown to increase the production of creatinine, without modification of its clearance [42].

Strengths and Limitations of This Study

This is the first study assessing the association between 25(OH)D concentration and a panel of immunologic and metabolic markers, in a large group of recently diagnosed treatment-naive persons living with HIV. In previous studies on vitamin D and HIV infection, a large majority of patients were receiving antiretroviral therapy, which could modify vitamin D metabolism, either directly, through the inhibition or activation of hydroxylation enzymes (protease inhibitors, efavirenz) [12], or indirectly, through the impact on proximal tubular function (tenofovir) [43]. Treatment of HIV infection also results in immune restoration, and, to a certain extent, in the control of inflammation, while antiretroviral treatment may interfere with lipid/glucose metabolism, kidney and adipocyte physiology.

A limitation of observational studies such as the present one is that normal or desirable values for 25(OH)D are a controversial issue, particularly when examining nonskeletal markers [4]. Severe vitamin D deficiency (25(OH)D<10 ng/mL) has been associated with a poorer clinical evolution of HIV infection in a previous study that showed a clear that different threshold 25(OH)D levels could be associated with different biological markers or clinical endpoints. Lastly, this cross-sectional analysis does not allow to conclude on the direction and causality of the observed relationships.

Conclusion

In the absence of antiretroviral treatment, vitamin D deficiency was highly prevalent in White and Black HIV-infected patients living in France. In this population, low 25(OH)D was associated with smoking, with lower CD4 counts and higher inflammatory markers. We also found that the influence of season on vitamin D status was different in Black and White persons and that the level of the inflammatory marker sTNFR2 was associated with severe vitamin D deficiency only in Black persons. This could reflect differences in body composition, in the allelic distribution of genes related to vitamin D metabolism [44] or in the sensitivity to vitamin D [45]. This difference should be taken into account in future studies.

Supporting Information

File S1 Members of the ANRS COPANA Cohort Study Group. (DOC)

Acknowledgments

The authors are grateful to all participants of the ANRS COPANA cohort study. They also thank Badra Boumaza, Abdellatif Essabbani and Tatiana Ferreto for data monitoring, Laurent Tran and Anne Persoz for data management, Remonie Seng for fruitful discussions, Barbara Antuna-Puente, Bernardete Besson-Lescure and Nadège Bruneel for help with multiplexed bead-based immunoassays, and the ANRS COPANA cohort study group.

Author Contributions

Conceived and designed the experiments: CL, CV, JC, CG, LM, JPV. Conducted statistical analyses: CL, LM. Critically revised the study group.

Conceived and designed the experiments: CL, CV, JC, CG, LM, JPV.

Analyzed the data: CL CV JC CG LM JPV JPB RC OB. Wrote the paper: CL LM JPV. Conducted statistical analyses: CL, LM. Critically revised the manuscript: CV JCS FB JC CG LM. Supervised 25-hydroxyvitamin D measurements: JCS.

References

1. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281.
2. Norman AW, Bouillon R (2010) Vitamin D nutritional policy needs a vision for the future. Exp Biol Med 235: 1034–1045.
3. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, et al. (2010) Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmunity Rev 9: 709–715.
4. Adams JS, Hewison M (2010) Update in vitamin D. J Clin Endocrinol Metab 95: 171–178.
5. Pilz S, Dobnig H, Nügels G, Heine RJ, Sticherler CD, et al. (2009) Vitamin D and mortality in older men and women. Clin Endocrinol 71: 666–672.
6. Dobnig H, Pilz S, Scharnagl H, Renner W, Scherhorn U, et al. (2008) Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168: 1340–1349.
7. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving HH, et al. (2010) Vitamin D levels and mortality in type 2 diabetes. Diabetes Care 33: 2258–2263.
8. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, et al. (2008) Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 26: 2984–2991.
9. Zittermann A, Schleithoff SS, Gotting C,uchs F, Kuhn J, et al. (2009) Calculated deficiency and 1-year mortality in cardiac transplant recipients. Transplantation 87: 118–124.
10. Pilz S, Iodice S, Zittermann A, Grant WB, Gundini S (2011) Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 58: 374–382.
11. Dao CN, Patel P, Overton ET, Rhiame F, Pals SL, et al. (2011) Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 52: 396–405.
12. Childs K, Welz T, Samarawickrama A, Post FA (2012) Effects of vitamin D on antiretroviral treatment. AIDS 26: 253–262.
13. Boxer RS, Dauser DA, Waljh SJ, Hager WD, Kenny AM (2008) The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. J Am Geriatr Soc 56: 454–461.
14. Schleithoff SS, Zittermann A, Torderich G, Berhold HK, Schiefe P, et al. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled study. Am J Clin Nutr 83: 734–759.
15. Hypponen E, Berry D, Cortina-Borja M, Power C (2010) 25-hydroxyvitamin D and pre-clinical alterations in inflammatory and hemostatic markers: a cross sectional analysis in the 1958 British birth cohort. PLoS ONE 5(5): e10801. doi: 10.1371/journal.pone.0010801.
16. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odfur N, et al. (2010) Vitamin D control T cell antigen receptor signaling and activation of human T cells. Nature Immunol 11: 349–354.
17. Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, et al. (2010) Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS ONE 5(1): e7870. doi: 10.1371/journal.pone.0007870.
18. Viard JP, Souberbielle JC, Kirk O, Knyz B, Losso M, et al. (2011) Vitamin D and vitamin D disease progression in HIV infection: results from the EuroSIDA study. AIDS 25: 1305–1315.
19. Sudfeld CR, Wang M, Aboud S, Giovannucci EL, Mugusi FM, et al. (2012) Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral Therapy. PLoS ONE 7(6): e400056. doi: 10.1371/journal.pone.00400056.
20. Ross AC, Judf S, Kumnr M, Hileman C, Sterer N, et al. (2011) Vitamin D is linked to cortisol intra-media thickness and immune reconstitution in HIV-positive individuals. Antiviral Ther 16: 533–563.
21. Aziz M, Livak B, Burke-Miller J, French A, Ghesly Mf, et al. (2013) Vitamin D insufficiency may impair CD4 recovery among Women’s Interagency HIV Study (WHIS) participants with advanced disease on HAART. AIDS 27: 573–580.
22. Vescini F, Cozzi-Lepri A, Boderi M, Re MC, Maggioni F, et al. (2011) Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr 58: 163–72.
23. Rossell CR, Giovannucci EL, Isanaka S, Aboud S, Mugusi FM, et al. (2011) Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among Tanzanian adults initiating antiretroviral therapy. J Infect Dis 207: 1370–1371.
24. Hammond E, McKinnon E, Gleaveen P, Williams R, Mallal S, et al. (2012) Association between 25-OH vitamin D and insulin is independent of lipotoxicity in HIV. Clin Endocrinol (Oxf) 76: 201–206.
25. Szep Z, Guaraldi G, Shah SS, Lo Re 3 rd V, Ratcliffle SJ, et al. (2011) Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS 25: 525–529.
26. Choi AI, Lo JC, Mulligan K, Schnell A, Kalapuc SG, et al. (2011) Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis 52: 941–944.

27. Shikuma CM, Seto T, Liang CY, Bennett K, DeGruttola V, et al. (2012) Vitamin D levels and markers of arterial dysfunction. AIDS Res Hum Retroviruses 28: 793–797.

28. Lai H, Gerstenblith G, Fishman EK, Brinker J, Kickler T, et al. (2012) Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis 54: 1747–1755.

29. Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, et al. (2012) Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients; the ANRS COPANA cohort. Antiviral Ther 17: 91–100.

30. Baker JV, Landgren JD (2011) Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 32: 945–951.

31. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, et al. (2010) Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus–infected patients: A case-control study nested within the French hospital database on HIV ANRS cohort CO4. Arch Intern Med. 170: 1228–1238.

32. Nixon DE, Landay AL (2010) Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 5: 498–503.

33. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, et al. (1993) The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 76: 1423–1427.

34. Allavena C, Delpierre C, Cuzin L, Rey D, Viget N, et al. (2012) High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J Antimicrob Chemother 67: 2222–2230.

35. Schwartz DR, Lazar MA (2011) Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 22: 259–265.

36. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Ellington PT, et al. (2012) Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA 109: 15449–15454.

37. Jorde K, Grønnes G (2011) Vitamin D and metabolic health with special reference to the effects of vitamin D on serum lipids. Prog Lipid Res 50: 303–132.

38. Lin E, Armstrong-Moore D, Liang Z, Sweeney JF, Torres WE, et al. (2011) Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity 19: 589–94.

39. Lorente-Cebrián S, Erikson A, Danlep T, Mejhert N, Dahliam I, et al. (2012) Differential effects of 1α,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur J Nutr 51: 333–342.

40. Menendez C, Lago M, Primo R, Baldelli R, Concheiro P, et al. (2003) Retinoic acid and vitamin D(3) powerfully inhibit on vitro leptin secretion by human adipose tissue. J Endocrinol 170: 1073–1079.

41. Tsuji K, Maeda T, Kase T, Matsunuma A, Horuchi N (2010) Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 25: 1711–1723.

42. Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD (2011) Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int 80: 1073–1079.

43. Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, et al. (2010) Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 54: 1127–1134.

44. Signorello LB, Shi J, Cai Q, Zheng W, Williams SM, et al. (2011) Common variation in Vitamin D pathway genes predicts circulating 25-hydroxyvitamin D levels among African Americans. PLoS ONE 6(12): e28623. doi:10.1371/journal.pone.0028623.

45. Wright NC, Chen L, Niu J, Neogi T, Javidi K, et al. (2012) Defining physiologically « normal » vitamin D in African Americans. Osteoporos Int 23: 2203–2209.